

**12 September 2024**

## Issue of Performance Share Rights

This notice is given under NZX Listing Rule 3.13.1 and relates to unlisted Performance Share Rights to acquire ordinary shares in the Company ('PSRs') issued under the Fisher & Paykel Healthcare 2022 Performance Share Rights Plan ('PSR Plan'), the 2022 Sub-Plan for France ('Sub-Plan for France') and the Fisher & Paykel Healthcare 2022 Performance Share Rights Plan – North America ('North America Plan').

Section 1: Issuer information	
Name of issuer	Fisher & Paykel Healthcare Corporation Limited
NZX ticker code	FPH
Class of financial product	Unlisted PSRs issued under the PSR Plan, the Sub-Plan for France and the North America Plan.
ISIN (If unknown, check on NZX website)	NZFAPE0001S2
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	254,587
Nominal value (if any)	Not applicable
Issue/acquisition/redemption price per security	No amount is payable for the grant of PSRs. One PSR gives the participant the potential to exercise that PSR for one ordinary share at no cost.
Nature of the payment (for example, cash or other consideration)	Not applicable
Amount paid up (if not in full)	Not applicable
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) <sup>1</sup>	254,587 PSRs represent approximately 0.0434% of the ordinary shares on issue
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	Not applicable
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of PSRs under the PSR Plan, the Sub-Plan for France and the North America Plan to incentivise selected employees to grow the Company and to attract, motivate and retain key employees.
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	Total number of PSRs on issue as at the date of this notice after the issue disclosed in this notice: 1,722,235
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	Not applicable

<sup>1</sup> The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Directors' resolution dated 28 August 2024.
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	The PSRs will be issued on the terms of the PSR Plan, the Sub-Plan for France and the North America Plan, as approved by the Board.
Date of issue/acquisition/redemption <sup>2</sup>	11 September 2024
<b>Section 3: Authority for this announcement and contact person</b>	
Name of person authorised to make this announcement	Marcus Driller
Contact person for this announcement	Marcus Driller
Contact phone number	+64 9 574 0110
Contact email address	Marcus.driller@fphcare.co.nz
Date of release through MAP	12 September 2024

---

<sup>2</sup> Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).